This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Atomoxetine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • atomoxetine licensed for the treatment of ADHD in children 6 years and older and in adolescents, under specialist supervision
    • a selective noradrenaline reuptake inhibitor, although the precise mechanism by which it works on ADHD is unknown
    • common adverse effects of treatment include abdominal pain, decreased appetite, nausea and vomiting, early morning awakening, irritability and mood swings. Increased heart rate and small increases in blood pressure were observed in clinical trials. For full details of adverse effects and contraindications, see the Summary of Product Characteristics

The Summary of Product Characteristics must be consulted before prescribing this drug.

Reference:

  1. NICE (March 2006). Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.